Literature DB >> 21872957

Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance.

Kristi Hendrickson1, Mark Phillips, Wade Smith, Lanell Peterson, Kenneth Krohn, Joseph Rajendran.   

Abstract

BACKGROUND AND
PURPOSE: Positron emission tomography (PET) imaging with [F-18] fluoromisonidazole (FMISO) has been validated as a hypoxic tracer. Head and neck cancer exhibits hypoxia, inducing aggressive biologic traits that impart resistance to treatment. Delivery of modestly higher radiation doses to tumors with stable areas of chronic hypoxia can improve tumor control. Advanced radiation treatment planning (RTP) and delivery techniques such as intensity modulated radiation therapy (IMRT) can deliver higher doses to a small volume without increasing morbidity. We investigated the utility of co-registered FMISO-PET and CT images to develop clinically feasible RTPs with higher tumor control probabilities (TCP).
MATERIALS AND METHODS: FMISO-PET images were used to determine hypoxic sub-volumes for boost planning. Example plans were generated for 10 of the patients in the study who exhibited significant hypoxia. We created an IMRT plan for each patient with a simultaneous integrated boost (SIB) to the hypoxic sub-volumes. We also varied the boost for two patients. RESULT: A significant (mean 17%, median 15%) improvement in TCP is predicted when the modest additional boost dose to the hypoxic sub-volume is included.
CONCLUSION: Combined FMISO-PET imaging and IMRT planning permit delivery of higher doses to hypoxic regions, increasing the predicted TCP (mean 17%) without increasing expected complications. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21872957      PMCID: PMC3225491          DOI: 10.1016/j.radonc.2011.07.029

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  42 in total

1.  Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study.

Authors:  Aste Søvik; Eirik Malinen; Øyvind S Bruland; Søren M Bentzen; Dag Rune Olsen
Journal:  Phys Med Biol       Date:  2006-12-29       Impact factor: 3.609

2.  Attenuation correction for a combined 3D PET/CT scanner.

Authors:  P E Kinahan; D W Townsend; T Beyer; D Sashin
Journal:  Med Phys       Date:  1998-10       Impact factor: 4.071

3.  Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.

Authors:  Danny Rischin; Rodney J Hicks; Richard Fisher; David Binns; June Corry; Sandro Porceddu; Lester J Peters
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

4.  Effects of oxygen on intrinsic radiation sensitivity: A test of the relationship between aerobic and hypoxic linear-quadratic (LQ) model parameters.

Authors:  David J Carlson; Robert D Stewart; Vladimir A Semenenko
Journal:  Med Phys       Date:  2006-09       Impact factor: 4.071

5.  Dose escalation to combat hypoxia in prostate cancer: a radiobiological study on clinical data.

Authors:  J Z Wang; X A Li; N A Mayr
Journal:  Br J Radiol       Date:  2006-08-02       Impact factor: 3.039

Review 6.  Hypoxia imaging-directed radiation treatment planning.

Authors:  J G Rajendran; K R G Hendrickson; A M Spence; M Muzi; K A Krohn; D A Mankoff
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

Review 7.  Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.

Authors:  Jean Bourhis; Jens Overgaard; Hélène Audry; Kian K Ang; Michele Saunders; Jacques Bernier; Jean-Claude Horiot; Aurélie Le Maître; Thomas F Pajak; Michael G Poulsen; Brian O'Sullivan; Werner Dobrowsky; Andrzej Hliniak; Krzysztof Skladowski; John H Hay; Luiz H J Pinto; Carlo Fallai; Karen K Fu; Richard Sylvester; Jean-Pierre Pignon
Journal:  Lancet       Date:  2006-09-02       Impact factor: 79.321

8.  Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer.

Authors:  Joseph G Rajendran; David L Schwartz; Janet O'Sullivan; Lanell M Peterson; Patrick Ng; Jeffrey Scharnhorst; John R Grierson; Kenneth A Krohn
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

Review 9.  Imaging hypoxia and angiogenesis in tumors.

Authors:  Joseph G Rajendran; Kenneth A Krohn
Journal:  Radiol Clin North Am       Date:  2005-01       Impact factor: 2.303

10.  Quality assurance of serial tomotherapy for head and neck patient treatments.

Authors:  D A Low; K S Chao; S Mutic; R L Gerber; C A Perez; J A Purdy
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-10-01       Impact factor: 7.038

View more
  51 in total

Review 1.  New techniques for assessing response after hypofractionated radiotherapy for lung cancer.

Authors:  Sarah A Mattonen; Kitty Huang; Aaron D Ward; Suresh Senan; David A Palma
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  Hyperpolarizing Concentrated Metronidazole 15 NO2 Group over Six Chemical Bonds with More than 15 % Polarization and a 20 Minute Lifetime.

Authors:  Roman V Shchepin; Jonathan R Birchall; Nikita V Chukanov; Kirill V Kovtunov; Igor V Koptyug; Thomas Theis; Warren S Warren; Juri G Gelovani; Boyd M Goodson; Sepideh Shokouhi; Matthew S Rosen; Yi-Fen Yen; Wellington Pham; Eduard Y Chekmenev
Journal:  Chemistry       Date:  2019-05-30       Impact factor: 5.236

Review 3.  Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilities.

Authors:  Wouter van Elmpt; Catharina M L Zegers; Marco Das; Dirk De Ruysscher
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

4.  Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements.

Authors:  Olivia J Kelada; Sara Rockwell; Ming-Qiang Zheng; Yiyun Huang; Yanfeng Liu; Carmen J Booth; Roy H Decker; Uwe Oelfke; Richard E Carson; David J Carlson
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

5.  Imaging Hypoxia with ¹⁸F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis.

Authors:  Mark Muzi; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2016-02-18       Impact factor: 10.057

Review 6.  Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview.

Authors:  Punit Sharma; Anirban Mukherjee
Journal:  Ann Transl Med       Date:  2016-02

7.  Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.

Authors:  B Henriques de Figueiredo; T Merlin; H de Clermont-Gallerande; M Hatt; D Vimont; P Fernandez; F Lamare
Journal:  Strahlenther Onkol       Date:  2013-11-01       Impact factor: 3.621

Review 8.  Molecular imaging of tumor hypoxia with positron emission tomography.

Authors:  Olivia J Kelada; David J Carlson
Journal:  Radiat Res       Date:  2014-03-27       Impact factor: 2.841

Review 9.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

10.  Quasi-Resonance Signal Amplification by Reversible Exchange.

Authors:  Thomas Theis; Nuwandi M Ariyasingha; Roman V Shchepin; Jacob R Lindale; Warren S Warren; Eduard Y Chekmenev
Journal:  J Phys Chem Lett       Date:  2018-10-10       Impact factor: 6.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.